Compound 1 Synthesis Through Cross-Coupling and Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthesis methods for Compound 1, a selective estrogen receptor alpha modulator/degrader (SERM/SERD), are inefficient, limiting the availability of this compound for clinical and potential commercial use.
Innovation Solution
A series of new and improved synthetic processes are developed, including cross-coupling reactions, reductions, and enantiomeric enhancements, utilizing transition metal catalysts, bases, and chiral acids to enhance the efficiency and yield of Compound 1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthesis methods are used for Compound 1, then the synthesis process is simpler, but the production efficiency and yield are low
Solution Approach 1:
The synthesis process is divided into multiple discrete steps including cross-coupling reactions, reductions, and enantiomeric enhancements. Each step is optimized independently with specific reagents and conditions, allowing for systematic improvement of overall productivity while managing complexity through modular process design.
Solution Approach 2:
The patent employs parameter changes by utilizing transition metal catalysts to alter reaction pathways and improve yields. Specific parameters such as catalyst type, base selection, and reaction conditions are optimized to enhance production efficiency without proportionally increasing process complexity.
2Manufacturing precision
If existing synthesis methods are used for Compound 1, then fewer reagents and catalysts are required, but the enantiomeric excess and yield are insufficient
Solution Approach 1:
Chiral acids are introduced as intermediaries to achieve enantiomeric enhancement. These chiral auxiliaries temporarily bind to the compound during synthesis, enabling selective formation of desired enantiomers with high enantiomeric excess, and are subsequently removed to yield the final product with improved stereochemical purity and overall yield.
Solution Approach 2:
The patent replaces conventional synthesis approaches with transition metal-catalyzed reactions that provide better control over stereochemistry. The catalytic mechanisms enable precise molecular transformations that achieve both high enantiomeric excess and improved yield simultaneously.
3Productivity
If existing synthesis methods are used for Compound 1, then the process is faster, but the production capacity is limited
Solution Approach 1:
The optimized synthesis process enables continuous production through efficient cross-coupling reactions and streamlined workup procedures. By improving reaction kinetics and reducing isolation/purification times, the process maintains continuous productive action, increasing overall production capacity without excessive time loss.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new processes significantly increase the production capacity of Compound 1, achieving high yields and enantiomeric excess, making it suitable for preclinical and clinical studies and future commercial applications.
Implementation Method 1
the reaction of a compound of formula (I) with a compound of formula (II) in the presence of a base and a transition metal catalyst wherein said X and X′ are suitable for cross-coupling of compound (I) with compound (II)
Implementation Method 2
comprising the reduction of a compound of formula (III) in the presence of a reducing agent
Implementation Method 3
crystallizing the enantiomerically enriched salt
Data Source
AI summary
Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.